Clinical trial
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus…
NCT00370552 · R-Pharm, Industry · Completed
Key facts
| NCT number | NCT00370552 |
|---|---|
| Title | A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer |
| Official title | A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer |
| Lead sponsor | R-Pharm, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg, 40 mg/m^2 + Bevacizumab, 15 mg/kg, Paclitaxel, 90 mg/m^2 + Bevacizumab |
| Enrollment | 136 |
| Start date | Mar 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Aug 31, 2006 |
| Last update posted | Mar 10, 2016 |
| Countries | France, Italy, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: